|
|||||
|
|
Efficacy and safety of ginsenoside-Rd for acute ischaemic stroke: a randomized, double-blind, placebo-controlled, phase II multicenter trial |
|
| Authors: | X Liu J Xia L Wang Y Song J Yang Y Yan H Ren G Zhao |
| Institution: | Department of Neurology, Xijing Hospital;;Department of Statistics, Fourth Military Medical University, Xi'an, Shaanxi, China;;Department of Neurology, First Hospital of Shaanxi province, Shaanxi;;Department of Neurology, Lanzhou Military Command General Hospital, Gansu;;Department of Neurology, First Affiliated Hospital of Chongqing University of Medical Sciences, Chongqing;;and Department of Neurology, First Affilliated Hospital of Kunming Medical College, Yunnan, China |
| Abstract: | Background and purpose: Ginsenoside-Rd is a selective competitive Ca Methods: A total of 199 patients were randomized equally to receive a 14-day infusion of placebo (group B), ginsenoside-Rd 10 mg (group A) or ginsenoside-Rd 20 mg (group C). Primary end-points were National Institutes of Health Stroke Scale (NIHSS) scores at 15 days. Secondary end-points were NIHSS scores and the Barthel Index at 8 days, the Barthel Index and the modified Rankin scale at 15 days and 90 days. The safety end-points included serious and non-serious adverse events, laboratory values and vital signs. Analysis was by intention to treat. Results: For the primary study outcome, there is significant difference amongst the three groups at 15 days in NIHSS scores ( P = 0.0003). Comparing group A with B and group B with C, the difference in the mean for NIHSS was significant in statistics ( P = 0.0004, P = 0.0009 respectively). This is no significant difference between group A and C ( P = 0.9640). For the secondary study outcome, ginsenoside-Rd did not improve neurological functioning. Incidence of serious and non-serious adverse events was similar amongst the three groups. Conclusions: Ginsenoside-Rd may be of some benefit in acute ischaemic stroke. |
| Keywords: | ginsenoside-Rd ischaemic stroke randomized trial |